© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
November 18, 2011
Dr. Jean-Paul Achker said there is room for improvement of response rates with current treatment approaches. "There may be a limited window of time to maximize anti-TNFÎ± therapy, as evidenced by the observed loss of response over time, the need to increase the dose of anti-TNFÎ± therapy, and immunogenicity," he said.
K.V. Narayanan Menon, MD, talks about Cleveland Clinic's patients with liver cancer.
"IL-28B receptor polymorphism is an important predictor of SVR in patients treated with pegylated interferon and ribavirin," said Binu John, MD at the Cleveland Clinic.
November 17, 2011
Ahmed Kandiel, MD, MPH, kicked off the 47th Annual Gastroenterology Update with a thorough review of the current treatment landscape for moderate to severe inflammatory bowel disease, including the potential risks for side effects for each biologic agent.